Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung

被引:7
|
作者
Qiong, Zhao [1 ]
Na, Wang Yi [1 ]
Bo, Wang [2 ]
Zhu, Zeng [1 ]
Ling, Peng [1 ]
Bo, Mou Hai [1 ]
Min, Tang Ye [1 ]
Lei, Zeng [1 ]
Na, Hu Dan [1 ]
Bo, Zhao [1 ]
Fang, Liu Jun [1 ]
Seng, Zheng Shu [3 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Thorac Oncol Dept, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Hepatobiliary & Pancreat Surg Dept, Hangzhou 310003, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Non-small cell lung cancer; Squamous cell carcinoma; Smoking; EGFR; PIK3CA; ALK; NEVER-SMOKERS; PIK3CA MUTATIONS; CANCER PATIENTS; ADENOCARCINOMA; MARKERS; WOMEN;
D O I
10.1016/j.lungcan.2014.11.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Female patients with squamous cell carcinomas of the lung (SQCLC) in China differ from male patients in that most females are life-long never/light smokers. We hypothesized that the clinical characteristics and mutation profiles of a spectrum of driver genes in Chinese female patients with advanced SQCLC would also differ from those of male patients. Patients and methods: We examined the pathological subtype of SQCLC retrospectively by immunohistochemistry (IHC) and screened 38 female and 40 male patients with IIIB/IV-stage SQCLC in China from 2009 to 2012. Mutation analyses of EGFR, PIK3CA, KRAS, and PTEN were performed using PCR-based DNA sequencing. FGFR1 amplification and ALK rearrangements were detected by fluorescent in situ hybridization (FISH). A Cox regression model was used to assess the association between clinical features and genomic mutation status. Results: There were significantly fewer female patients with a history of smoking than males (5.3% vs. 90%; P < 0.001). A younger average age at diagnosis (54.5 vs. 61 years; P = 0.032) and a higher percentage of peripheral-type disease (47.4% vs. 25.0%; P = 0.040) were observed in females. No difference in ECOG score, tumor size, metastatic status, or overall survival between females and males was seen. PIK3CA mutations were significantly less common in female patients than males (0/38 vs. 6/40; P = 0.026). However, no significant difference in the mutational frequencies of EGFR, KRAS, PTEN, ALK, or FGFR1 was observed between females and males. Conclusions: Our data demonstrated that female patients with SQCLC are apparently a subtype, with a significantly lower percentage having a smoking history, a younger average age at diagnosis, a higher percentage of peripheral-type disease on radiological presentation, and a lower frequency of PIK3CA mutations. Given the similar survival outcomes between the genders, whether it is a distinct disease entity needs to be studied further in larger populations. (C)2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:117 / 121
页数:5
相关论文
共 50 条
  • [1] Identification of driver gene alterations in Chinese female patients with squamous cell carcinomas of the lung.
    Wang, Yi Na
    Zhao, Qiong
    Wang, Bo
    Zeng, Zhu
    Pang, Ling
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Frequency of oncogenic alterations in five driver genes in Chinese female lung adenocarcinoma.
    Xu, Ren
    Ma, Jie
    Xie, Li-Qun
    Tao, Hui-Qing
    Wei, Bing
    Guo, Yong-Jun
    Bao, Wen-Jing
    Tong, Guang-Quan
    Ding, Lu
    Zhan, Min-Ning
    Yong, Ma Zhi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Erlotinib in patients with advanced lung squamous cell carcinoma
    Chi-Lu Chiang
    Chun-Ming Tsai
    Teh-Ying Chou
    Yuh-Min Chen
    Shinn-Liang Lai
    Jen-Fu Shih
    Chao-Hua Chiu
    Yu-Chin Lee
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 203 - 208
  • [4] Erlotinib in patients with advanced lung squamous cell carcinoma
    Chiang, Chi-Lu
    Tsai, Chun-Ming
    Chou, Teh-Ying
    Chen, Yuh-Min
    Lai, Shinn-Liang
    Shih, Jen-Fu
    Chiu, Chao-Hua
    Lee, Yu-Chin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 203 - 208
  • [5] Targeted Therapies for Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung
    Thomas E. Stinchcombe
    Current Treatment Options in Oncology, 2013, 14 : 568 - 579
  • [6] Targeted Therapies for Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung
    Stinchcombe, Thomas E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (04) : 568 - 579
  • [7] 5 DRIVER GENES IN CHINESE FEMALE LUNG ADENOCARCINOMA
    Han, Baohui
    Wei, Bing
    Dong, Yu
    Ma, Zhiyong
    Ma, Jie
    Tao, Huiqing
    Xiong, Hui
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1255 - S1255
  • [8] Clinical Outcomes in Metastatic Squamous Lung Cancer with Targetable Driver Alterations
    Lewis, W.
    Simon, G.
    Mott, F.
    Papadimitrakopoulou, V.
    Rinsurongkawong, W.
    Lewis, J.
    Lee, J.
    Roth, J.
    Swisher, S.
    Heymach, J.
    Zhang, J.
    Lam, V.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S308 - S308
  • [9] Genomic features of Chinese lung squamous cell carcinoma patients
    Zhao, Z.
    Chen, Y.
    Kong, W.
    Yu, Z.
    He, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S253 - S253
  • [10] Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung
    Santos, Edgardo S.
    Rodriguez, Estelamari
    CLINICAL LUNG CANCER, 2022, 23 (06) : 457 - 466